Q3 2025 Cumberland Pharmaceuticals Inc Earnings Call Transcript

Nov 4, 2025 / 09:30 PM GMT

Release Date Price: $2.66 (-3.62%)

Transcript 10-Q8-K

Key Points

Positve

Cumberland Pharmaceuticals Inc (CPIX) announced a new addition to their commercial product portfolio with the joint commercialization of Talesia, an FDA-approved treatment for Helicobacter pylori infections.
The company reported a 12% year-to-date revenue growth over the same period last year, with total revenues of $30.9 million for the first nine months of 2025.
CPIX's portfolio of FDA-approved brands delivered combined revenues of $8.3 million during the third quarter.
The company has reduced its total debt by $10 million since the end of 2024, improving its financial position.
CPIX continues to generate positive cash flow from operations, which increased to nearly $5 million through September 2025.

Negative

Third-quarter sales were impacted by a delay in some Crystallos and Caldeor shipments.
The company reported an adjusted loss of $0.8 million or $0.06 per share for the third quarter.
CPIX faces increased substitution of its Crystallos product by pharmacies in favor of generic alternatives, impacting sales.
Total operating expenses for the third quarter were $10.3 million, contributing to a net loss for the quarter.
The company continues to face challenges from generic competition, particularly affecting its Crystallos product.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CPIX.OQ - Cumberland Pharmaceuticals Inc
Q3 2025 Cumberland Pharmaceuticals Inc Earnings Call
Nov 04, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Cumberland Pharmaceuticals 3rd quarter 2025 Financial Report and Company update.

This call is being recorded at the company's request and will be archived on its website for one year from today's date.

I would now like to turn it over to Emily Kent from the Dalton Agency who handles Cumberland's communications. Emily, please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hello, everyone, and thank you for joining us today.

This afternoon, Cumberland issued a press release announcing its 3rd

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.